BR0108959A - Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico - Google Patents

Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico

Info

Publication number
BR0108959A
BR0108959A BR0108959-5A BR0108959A BR0108959A BR 0108959 A BR0108959 A BR 0108959A BR 0108959 A BR0108959 A BR 0108959A BR 0108959 A BR0108959 A BR 0108959A
Authority
BR
Brazil
Prior art keywords
compositions
nucleic acid
poloxamine
acid delivery
improved
Prior art date
Application number
BR0108959-5A
Other languages
English (en)
Inventor
Francois Nicol
Jijun Wang
Michael Coleman
Fiona Maclaughlin
Alain Rolland
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Publication of BR0108959A publication Critical patent/BR0108959A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES DE POLOX‰MERO OU POLOXAMINA MELHORADAS PARA DISTRIBUIçãO DE áCIDO NUCLéICO". A presente invenção refere-se a composições e métodos para a introdução de uma molécula de ácido nucléico em uma célula, preferivelmente por um método de distribuição de voltagem de pulso, para a expressão de uma proteína, peptídeo, RNA anti-sentido, ribozima ou polipeptídeo.
BR0108959-5A 2000-03-03 2001-03-02 Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico BR0108959A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18723600P 2000-03-03 2000-03-03
US24227700P 2000-10-20 2000-10-20
PCT/US2001/006831 WO2001065911A2 (en) 2000-03-03 2001-03-02 Improved poloxamer and poloxamine compositions for nucleic acid delivery

Publications (1)

Publication Number Publication Date
BR0108959A true BR0108959A (pt) 2003-10-14

Family

ID=26882846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108959-5A BR0108959A (pt) 2000-03-03 2001-03-02 Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico

Country Status (7)

Country Link
US (2) US20030206910A1 (pt)
EP (1) EP1309904A4 (pt)
JP (1) JP2003525613A (pt)
AU (1) AU2001241958A1 (pt)
BR (1) BR0108959A (pt)
CA (1) CA2401239A1 (pt)
WO (1) WO2001065911A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066149A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
DE60144338D1 (de) * 2000-10-20 2011-05-12 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände
EP1232758A1 (fr) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucléotide formulé en vue d'un transfert intracellulaire amélioré
FR2835749B1 (fr) * 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
WO2004028442A2 (en) * 2002-09-26 2004-04-08 Pfizer Products Inc. Use of excipients to increase dna uptake by swine muscle cells
US7381422B2 (en) 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
CA2508279A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US7850645B2 (en) 2005-02-11 2010-12-14 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
WO2006086775A2 (en) * 2005-02-11 2006-08-17 Duke University Methods and compositions for reducing systemic toxicity of vectors
US8480651B2 (en) * 2007-08-02 2013-07-09 Covidien Lp Cannula system
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
US20090202467A1 (en) * 2008-02-08 2009-08-13 Bock Richard W Sclerotherapy for varicose veins
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009108891A2 (en) * 2008-02-29 2009-09-03 Egen, Inc. Modified poloxamers for gene expression and associated methods
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
JP5947723B2 (ja) * 2009-11-17 2016-07-06 ノバルティス アーゲー コンタクトレンズの消毒のための過酸化水素溶液及びキット
WO2011097384A2 (en) * 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
EP2729192B1 (en) * 2011-07-05 2019-01-02 The Research Foundation for The State University of New York Compositions and methods for spinal disc repair and other surgical and non-surgical indications
EP3868888A1 (en) * 2012-02-29 2021-08-25 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retroviral transduction using poloxamers
WO2014194137A1 (en) * 2013-05-29 2014-12-04 Biogen Idec Ma Inc. Methods of evaluating cell culture additives
EP3125945B1 (en) * 2014-04-01 2019-09-11 Institut National de la Sante et de la Recherche Medicale (INSERM) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
FR3030147B1 (fr) 2014-12-11 2018-03-16 Mmt Sa Actionneur avec modules statorique et rotorique enrobes
CA2936070C (en) 2015-07-14 2023-07-04 Professional Compounding Centers Of America (Pcca) Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
WO2017214468A1 (en) * 2016-06-09 2017-12-14 Tien Yang Der Nanodroplet compositions for the efficient delivery of anti-cancer agents
KR102544922B1 (ko) * 2017-12-21 2023-06-16 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
WO2020039445A1 (en) * 2018-08-23 2020-02-27 Zion Medical B.V Pharmaceutical compositions comprising integration-promoting peptides
WO2020115114A1 (en) * 2018-12-04 2020-06-11 Sirion Biotech Gmbh Viral transduction using poloxamines
CA3131824A1 (en) * 2019-03-11 2020-09-17 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
JP7853100B2 (ja) 2019-06-05 2026-04-28 オーチャード セラピューティクス（ヨーロッパ）リミテッド 真核細胞を修飾するための組成物及び方法
CA3157966A1 (en) * 2019-10-16 2021-04-22 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
EP4139450A1 (en) * 2020-04-20 2023-03-01 SiO2 Medical Products, Inc. Nucleic acid and cell preservative compositions and methods of use
IL299806A (en) * 2020-07-17 2023-03-01 Surge Therapeutics Inc Preparations and compositions comprising polymer combination preparations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
JP3368603B2 (ja) * 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US5545130A (en) * 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US6132419A (en) * 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5507724A (en) * 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5676071A (en) * 1994-03-21 1997-10-14 Techform Engineering Ag Method and device for introducing a liquid or gaseous treatment medium into a flue gas flow
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US6040190A (en) * 1995-06-02 2000-03-21 Avl Medical Instruments Ag Method for determining the concentration C of an absorbent homogeneously distributed in a carrier
US5686071A (en) * 1995-06-06 1997-11-11 Per Immune Holdings, Inc. Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US7176186B1 (en) * 1997-09-16 2007-02-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6379966B2 (en) * 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5704908A (en) * 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
FR2759298B1 (fr) * 1997-02-10 1999-04-09 Rhone Poulenc Rorer Sa Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
US6884430B1 (en) * 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US20020102729A1 (en) * 1998-06-08 2002-08-01 Maclaughlin Fiona Formulations for electroporation
EP1278551A2 (en) * 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics

Also Published As

Publication number Publication date
EP1309904A1 (en) 2003-05-14
WO2001065911A2 (en) 2001-09-13
EP1309904A4 (en) 2006-03-29
JP2003525613A (ja) 2003-09-02
US20060013883A1 (en) 2006-01-19
CA2401239A1 (en) 2001-09-13
WO2001065911A9 (en) 2005-11-17
AU2001241958A1 (en) 2001-09-17
US20030206910A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
CN116115629A (zh) 核酸产品及其施用方法
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
EP1832599A3 (en) Albumin fusion proteins
BR0013542A (pt) Moléculas b7-4 e usos para as mesmas
EP0692972A4 (en) PROCESS FOR PROVIDING PROFILEABLE COMPOSITIONS TO PILED FOLLICLES
DE60203692D1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
NZ594877A (en) Nucleic acids and proteins from streptococcus groups A & B
AR052441A1 (es) Suspension no acuosa inyectable
WO2005003296A3 (en) Albumin fusion proteins
EP0804563A4 (en) Antisense oligonucleotide generators
WO2001059094A3 (en) Method of regulating transcription in a cell by altering remodeling of cromatin
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR9811592A (pt) Oxidase de citocinina
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
Sikora et al. Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vivo
BR9909918A (pt) Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2001036626A3 (en) Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
WO2002083891A3 (en) Nucleic acids for inhibiting hairless protein expression and methods of use thereof
WO2001053339A3 (en) Egg specific surface proteins
DE60125569D1 (de) 13245, eine neue, humane protein kinase vom typ myotonische dystrophie protein kinase und anwendungen davon
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
DE60219601D1 (de) Durch liposome vermittelte dna verabreichung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.